Wang Meng, Yang Qiyu, Zhu Lixia, Jin Lei
Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
World J Mens Health. 2022 Oct;40(4):570-579. doi: 10.5534/wjmh.220017. Epub 2022 May 31.
This study aimed to evaluate the influences of SARS-CoV-2 vaccination (CoronaVac) on male fertility and investigate the impact of a history of the CoronaVac vaccination in males on gamete and embryo development and fertilization (IVF) outcomes.
A prospective cohort study enrolled couples undergoing IVF cycles between June and August 2021 at Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology in China. According to the history of SARS-CoV-2 vaccination in males, the participants were divided into the vaccination group and the non-vaccination group. A self-controlled study of semen analyses for males before and after CoronaVac vaccination was conducted. Baseline characteristics were matched using propensity score matching. Participants were categorized into the unexposed group (non-vaccination) and exposed group (vaccination), and the population was 271 for each. Semen parameters and IVF outcomes were the main outcomes.
Generally, no statistically significant differences were exhibited between the matched cohorts regarding embryo developmental parameters, including fertilization rate, cleavage rate, high-quality embryo rate, blastocyst formation rate, and available blastocyst rate, as well as clinical outcomes, such as implantation rate, biochemical pregnancy rate, and clinical pregnancy rate. Moreover, males after vaccination seemed to have fluctuating semen parameters including increased semen volume, lower motility, and decreased normal forms of sperm, while the motile sperm counts were similar. In addition, all semen parameters were above the lower reference limits.
Our findings suggested that CoronaVac vaccinations in males may not have adverse effects on patient performance or the gamete and embryonic development potential during assisted reproductive technology (ART) treatments.
本研究旨在评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗（科兴新冠疫苗）接种对男性生育能力的影响，并调查男性接种科兴新冠疫苗史对配子、胚胎发育及受精（体外受精）结局的影响。
一项前瞻性队列研究纳入了2021年6月至8月在中国华中科技大学同济医学院附属同济医院生殖医学中心接受体外受精周期治疗的夫妇。根据男性的SARS-CoV-2疫苗接种史，将参与者分为接种组和未接种组。对男性接种科兴新冠疫苗前后的精液分析进行自身对照研究。使用倾向得分匹配法匹配基线特征。参与者被分为未暴露组（未接种）和暴露组（接种），每组各271人。精液参数和体外受精结局为主要观察指标。
总体而言，在匹配队列之间，胚胎发育参数（包括受精率、卵裂率、优质胚胎率、囊胚形成率和可用囊胚率）以及临床结局（如着床率、生化妊娠率和临床妊娠率）方面，未显示出统计学上的显著差异。此外，接种疫苗后的男性精液参数似乎存在波动，包括精液量增加、活力降低和正常形态精子减少，而活动精子计数相似。此外，所有精液参数均高于较低参考限值。
我们的研究结果表明，男性接种科兴新冠疫苗可能不会对辅助生殖技术（ART）治疗期间的患者表现或配子及胚胎发育潜力产生不利影响。
